There were recurrent mutations in core AML driver genes, including <i>TET1</i>, <i>FLT3,</i> and <i>TP53</i>, and relapsed samples demonstrated increased involvement and complexity of the signaling system. Here, TP53 is linked to acute myeloid leukemia.